A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

Inclusion Criteria Concurrent Medication: Allowed: * Antiretrovirals if on a stable dose for at least the past 3 months. Patients must have: * HIV-1 infection with CD4 count 300-549 cells/mm3. * No AIDS-defining condition. * Been on a stable dose of antiretroviral for the past 3 months, if taking antiretrovirals. NOTE: * KS is permitted if not requiring systemic therapy. Prior Medication: Allowed: * Prior antiretrovirals. Exclusion Criteria Concurrent Medication: Excluded: * Systemic chemotherapy for KS. * Treatment for malignancy other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. Patients with the following prior conditions are excluded: * History of any illness that would interfere with study. * Acute infection requiring prescription therapy within the past month, other than genital herpes and oral or vaginal candidiasis. Prior Medication: Excluded: * Prior HIV-1 Immunogen. Unwilling to use effective safe sex practices. Active substance abuse.